Home » Newsletters » BioWorld Asia

BioWorld Asia

March 3, 1999

View Archived Issues

Narcolepsy Research Locates Potential Gene-Marker Cause

MorphoSys IPO To Value Antibody Firm At US$85M

Biota Flu-Drug Rejection Sends Stock Into Nosedive

Cortecs Ending Phase III Trials Early To Gather Data

Biostar Subsidiary To Target Hormone-Dependent Cancers

Sanofi Doubles Funding For Cerep In Targets Deal

PPL Therapeutics' Phase II Anti-Infective Data Positive

GlycoDesign Cancer Drug May Block Chemo Damage

U.K. Sector Enlarging Fast, Says BioIndustry Association

Flamel Blames R&D Costs, Phase III Trials For Net Loss

Pharming Revenues Rise; Plans Pompe's Drug Launch

Plant Genomics Program May Seek More Partners

Nations Clash In Cartagena Over Biosafety Food Rules

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 24, 2026.
Have brain-computer interfaces finally arrived?
BioWorld
More and more individuals now have chronically implanted brain-computer interface (BCI) systems in their heads. Devices that can record and stimulate neural...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 23, 2026
In the clinic for June 22, 2026
BioWorld
Clinical updates for biopharma and med tech, including data readouts and publications: Alkermes, Boehringer, Cambrian, F2G, Intrabio, Lexeo, Memo, Novocure,...
2026 marks critical turning point for BCI technology
BioWorld
Decades of research are helping unravel the “black box” of the brain. The second article in BioWorld’s series on the Brain-Computer Interface (BCI) field looks at...